Clinical Trial

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2023-07-10; most recent amendment 2026-06-11.
Status change: Not Yet Recruiting → Recruiting 2024-01-02
Trial Details
NCT Number NCT05950945
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Breast Cancer
Enrollment 250 participants
Start Date 2023-12-30
Primary Completion 2027-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12